Asian venture ASLAN raises $22m in new funding
This article was originally published in Scrip
Singapore-based ASLAN Pharmaceuticals has closed a Series B financing in which it has raised $22m to support its development portfolio and the licensing in of additional molecules.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.